The emerging role of reactive oxygen species in cancer therapy
- 1 September 2004
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (13), 1934-1940
- https://doi.org/10.1016/j.ejca.2004.02.031
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2004
- Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain MetastasesJournal of Clinical Oncology, 2003
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 2003
- Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialJournal of Clinical Oncology, 2003
- Mitochondrion as a Novel Target of Anticancer ChemotherapyJNCI Journal of the National Cancer Institute, 2000
- Adriamycin and its iron(III) and copper(II) complexesBiochemical Pharmacology, 1988
- Combined Effect of Procarbazine and Ionizing Radiation on Mouse Jejunal CryptsChemotherapy, 1978
- Electron-affinic SensitizationInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1969
- The enhancement of the after effect of ionizing radiation by a cytotoxic methylhydrazine derivativeEuropean Journal of Cancer (1965), 1966
- METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HÆMATOSARCOMA AND LEUKÆMIAThe Lancet, 1963